During the last session, Bluebird bio Inc (NASDAQ:BLUE)’s traded shares were 3.87 million, with the beta value of the company hitting 0.72. The 52-week high for the BLUE share is $5.53, that puts it down -1743.33 from that peak though still a striking 3.33% gain since the share price plummeted to a 52-week low of $0.29. The company’s market capitalization is $57.93M, and the average intraday trading volume over the past 10 days was 6.67 million shares, and the average trade volume was 6.46 million shares over the past three months.
Bluebird bio Inc (BLUE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.20. BLUE has a Sell rating from 1 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.31.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bluebird bio Inc (NASDAQ:BLUE) trade information
Bluebird bio Inc (BLUE) registered a -1.68% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.68% in intraday trading to $0.30, hitting a weekly high. The stock’s 5-day price performance is -17.84%, and it has moved by -41.90% in 30 days. Based on these gigs, the overall price performance for the year is -91.86%. The short interest in Bluebird bio Inc (NASDAQ:BLUE) is 47.71 million shares and it means that shorts have 9.53 day(s) to cover.
The consensus price target of analysts on Wall Street is $12.5, which implies an increase of 97.6% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $25 respectively. As a result, BLUE is trading at a discount of -8233.33% off the target high and -1566.67% off the low.
Bluebird bio Inc (BLUE) estimates and forecasts
Statistics show that Bluebird bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. Bluebird bio Inc (BLUE) shares have gone down -69.26% during the last six months, with a year-to-date growth rate more than the industry average at 30.05% against 18.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 60.68% this quarter and then jump 50.00% in the quarter after that. In the rating firms’ projections, revenue will increase 141.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 25.8M as predicted by 7 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 37.72M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 7.83M and 18.57M respectively. In this case, analysts expect current quarter sales to grow by 229.38% and then jump by 103.10% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 28.98%. While earnings are projected to return 18.98% in 2024, the next five years will return 45.80% per annum.
BLUE Dividends
Bluebird bio Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Bluebird bio Inc (NASDAQ:BLUE)’s Major holders
Bluebird bio Inc insiders own 0.63% of total outstanding shares while institutional holders control 43.69%, with the float percentage being 43.96%. BLACKROCK INC. is the largest shareholder of the company, while 196.0 institutions own stock in it. As of 2024-06-30, the company held over 15.44 million shares (or 14.1544% of all shares), a total value of $15.2 million in shares.
The next largest institutional holding, with 10.3 million shares, is of VANGUARD GROUP INC’s that is approximately 9.4422% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $10.14 million.
